Payment overview · 2025
General Payments
$635.26
40 reported records · 14 companies
Healthcare provider profile · identity verified
Nancy Briley Walker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CROWLEY, LA · NPI 1235279043
Verified facts
What the public records show
CMS Open Payments records show Nancy Briley Walker, M.D. received $635.26 in general payments during 2025 across 40 reported records.
ABBVIE INC. accounted for 28.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $183.00 | 28.8% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $86.60 | 13.6% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $66.96 | 10.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.01 | 10.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.21 | 5.7% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $35.13 | 5.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.72 | 5.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.28 | 4.1% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.60 | 4.0% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $18.43 | 2.9% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.87 | 2.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.94 | 2.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.96 | 2.2% | 1 | 2025 |
| CorVista Health, Inc. | Unresolved — no canonical attribution shown | $13.55 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $635.26 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $118.93 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.81 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $66.96 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.11 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.81 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.21 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $35.13 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.89 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.49 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.28 | 5 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| CorVista System Normalized: corvista system |
Device | CorVista Health, Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 656 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 543 | 114 |
| Omeprazole | Omeprazole | 453 | 102 |
| Gabapentin | Gabapentin | 425 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 393 | 93 |
| Pravastatin Sodium | Pravastatin Sodium | 365 | 72 |
| Glimepiride | Glimepiride | 317 | 58 |
| Furosemide | Furosemide | 298 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 293 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 288 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 279 | 61 |
| Lisinopril | Lisinopril | 277 | 63 |
| Buspirone Hcl | Buspirone Hcl | 274 | 53 |
| Metformin Hcl Er | Metformin Hcl | 272 | 54 |
| Sertraline Hcl | Sertraline Hcl | 257 | 51 |
| Enalapril Maleate | Enalapril Maleate | 248 | 54 |
| Januvia | Sitagliptin Phosphate | 245 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 200 | 37 |
| Trazodone Hcl | Trazodone Hcl | 193 | 41 |
| Carvedilol | Carvedilol | 189 | 36 |
| Losartan Potassium | Losartan Potassium | 186 | 42 |
| Potassium Chloride | Potassium Chloride | 176 | 53 |
| Tramadol Hcl | Tramadol Hcl | 171 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 31 |
| Eliquis | Apixaban | 149 | 15 |
| Metformin Hcl | Metformin Hcl | 140 | 36 |
| Alprazolam | Alprazolam | 129 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 125 | 22 |
| Meloxicam | Meloxicam | 125 | 30 |
| Ezetimibe | Ezetimibe | 122 | 22 |
| Famotidine | Famotidine | 121 | 20 |
| Montelukast Sodium | Montelukast Sodium | 116 | 19 |
| Ozempic | Semaglutide | 112 | 16 |
| Simvastatin | Simvastatin | 109 | 27 |
| Allopurinol | Allopurinol | 108 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 19 |
| Prednisone | Prednisone | 103 | 75 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 21 |
| Donepezil Hcl | Donepezil Hcl | 101 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 20 |
| Bupropion Xl | Bupropion Hcl | 93 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 27 |
| Cefdinir | Cefdinir | 89 | 69 |
| Valsartan | Valsartan | 85 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 37 |
| Alendronate Sodium | Alendronate Sodium | 76 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 15 |
| Propranolol Hcl | Propranolol Hcl | 71 | 14 |
| Minoxidil | Minoxidil | 67 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 23 |
| Azithromycin | Azithromycin | 64 | 54 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 11 |
| Tradjenta | Linagliptin | 59 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 58 | suppressed |
| Clonazepam | Clonazepam | 55 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 13 |
| Mirtazapine | Mirtazapine | 52 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 51 | 13 |
| Warfarin Sodium | Warfarin Sodium | 51 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Finasteride | Finasteride | 48 | suppressed |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Jardiance | Empagliflozin | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | suppressed |
| Indapamide | Indapamide | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 16 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Torsemide | Torsemide | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 22 |
| Primidone | Primidone | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 15 |
| Latanoprost | Latanoprost | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Lactulose | Lactulose | 31 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Colchicine | Colchicine | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 17 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Jantoven | Warfarin Sodium | 24 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 23 | 11 |
| Nystatin | Nystatin | 23 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 22 |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 18 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Ertapenem | Ertapenem Sodium | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 12 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 12 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $635.26 · 40 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, CONTRAVE, Cologuard Collection Kit, CorVista System, EVKEEZA, FARXIGA, GARDASIL 9, JARDIANCE, MOUNJARO, QULIPTA, Qelbree, RELISTOR, TRULANCE, UBRELVY, VOQUEZNA, VRAYLAR, WATCHMAN FLX, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error